Exchange: NASDAQ·Updated 04:48 PM EDT
RNTX logo

RNTX Rein Therapeutics, Inc. Common Stock

$0.63
$0.042
(7.17%)
Today
Closed $0.628
$0.002
(0.32%)
After Hours
Mkt Cap$50.55M
Vol1.37M

About RNTX

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.
45

Neutral Sentiment

How do you feel about RNTX?

ItsAllAboutBeingFirst
Some cheap plays ready to come back $rntx $airs $kzia $poet - definitely have catalysts and some easy money to make at these levels
1
4
BrianWindsor
Insulin is a peptide. So are GLP-1s. So are a lot of compounds being sold in wellness clinics right now. "Peptide" tells you what a molecule is made of. It doesn't tell you whether it's safe or whether it works. That's what clinical trials are for. LTI-03 is a peptide too, and we're testing it the only way that counts, in a randomized, placebo-controlled Phase 2 trial in IPF. Our CSO Cory Hogaboam explains the difference here. $RNTX
3
longterminvs
$RNTX Within the span of 24–48 hours, the competitive landscape for next-generation IPF therapies saw: 1) Bristol Myers Squibb (BMY): Delivered confusing, non-linear Phase 3 dose data on their oral LPA1 antagonist. 2) Syndax (SNDX): Completely shut down their Phase 2 IPF pipeline asset. For a micro-cap biotech like Rein Therapeutics, every high-profile trial failure or mixed result from larger competitors clears potential clutter from the future market. If LTI-03’s ongoing Phase 2 RENEW trial delivers clean safety and clear FVC preservation in its upcoming interim readouts, Rein will stand out even further as one of the few biotechs with a viable, disease-modifying, inhaled asset in a multi-billion dollar market.
1
longterminvs
$RNTX If we have good data the BMY mixed data bodes well for us. With respect to anything IPF it's known as a drug graveyard because nothing seems to work. So, based on the history in this space and the share price it's assumed RNTX is a failure also.
1
SevenPhigs27
$RNTX It would be kind of wierd to not using social media to get the message out for free.
1
Dcvcool
$RNTX it’s kind of weird to have IR here on the chat board Not something I want personally
1
NolAsrtormZ
$RNTX im not in yet. They have cash on hand. iPf interim data due 2nd half of 2026- which is anytime now. Nice institutional ownership Backburner play
1
wolfcyd3
$RNTX someone is exiting a large position here. Hopefully its just a margin call and nothing else
Bigjohnson99
$RNTX what the fuck happened here? Stop at $.72 got tripped. Either some news slipped out or someone’s trying to scare people out of their positions. Guess it worked for me. I’ll slowly add some back after doing some digging.
Bigjohnson99
$RNTX more IPF news out today after the $BMY results this am, $SNDX shits the bed and ends their ph2 trial after poor results. Tough indication to get move ahead with it seems
Bigjohnson99
$RNTX I’m in for 30k shares as a starter today. I’ll add another 30-40k slowly over the next week or so. I think this has potential to move.
BrianWindsor
One of the simplest questions in IPF is also one of the most important: Does the lung keep working? Our CSO, Cory Hogaboam, has spent more than 25 years studying lung fibrosis. In this short video, he explains how he thinks about lung function, FVC, and what we ultimately hope to learn from our Phase 2 RENEW trial. $RNTX

Advertisement|Remove ads.